Boehringer Ingelheim and Simcere Pharmaceutical Group have entered into a global licensing and collaboration agreement granting Boehringer exclusive rights outside Greater China to develop, manufacture and commercialise SIM0709, a preclinical bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease (IBD). The deal, which is valued up to US$1.26 B, will grant Boehringer ex-China rights to advance a differentiated dual pathway asset while enabling Simcere to retain domestic commercial control. Strategically, the collaboration strengthens Boehringer’s immunology pipeline, accelerates Simcere’s global ambitions, and underscores growing competition in next‑generation IBD biologics.